Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Dalian BIO-CHEM Company Limited (603360.SS)
Dalian, CN
Established in 2003 and headquartered in Dalian, China, Dalian BIO-CHEM Company Limited specializes in the manufacture and distribution of antimicrobial agents, specifically bactericides, antiseptics, and fungicides. These products serve a broad spectrum of industrial sectors across continents, including Europe, North and South America, the Middle East, Africa, and Asia. The company's offerings perform various crucial functions: they act as disinfectants and effective algaecides for water treatment systems in industries like petrochemicals, power generation, central air conditioning, and industrial cooling. Additionally, they provide corrosion protection within aqueous systems, found in products such as emulsions, mineral slurries, pigment dispersions, adhesives, tackifiers, metalworking fluids, and cosmetics. Their solutions also extend to the aqueous formulations used in leather, paints, coatings, textiles, and dyeing processes. Furthermore, Dalian BIO-CHEM's products combat mildew and algae, and the company offers a specialized dry film preservative tailored for paints and coatings.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.27% | -11.45% | -28.00% | -31.39% | -43.89% | -39.76% | -4.95% | +268.31% | +288.98% | +685.83% | +685.83% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%+31.4% ★ Q1'26: -41.2% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%-38.8% Q1'26: -58.0% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+26.7% ★ Q1'26: -19.0% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+21.4% ★ Q1'26: +10.6% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+17.2% ★ Q1'26: +4.7% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%-1.6% ★ Q1'26: -5.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×2.29× ★ Q1'26: 5.66× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
410.36M
est: 452.00M (-9.2%)
|
528.17M
est: 519.70M (+1.6%)
|
871.90M
est: 988.50M (-11.8%)
|
749.54M
est: 1.18B (-36.2%)
|
1.01B
est: 857.00M (+17.4%)
|
1.26B
est: 1.32B (-4.7%)
|
1.07B
est: 1.08B (-1.2%)
|
1.31B
est: 1.18B (+11.6%)
|
1.72B
est: 1.79B (-3.7%)
|
2.19B
2.19B – 2.19B
+22.3% YoY
|
2.59B
2.59B – 2.59B
+18.3% YoY
|
| EBITDA |
152.48M
est: 173.94M (-12.3%)
|
197.08M
est: 199.99M (-1.5%)
|
404.48M
est: 380.40M (+6.3%)
|
310.66M
est: 452.18M (-31.3%)
|
352.91M
est: 329.80M (+7.0%)
|
536.99M
est: 507.28M (+5.9%)
|
454.73M
est: 415.23M (+9.5%)
|
490.58M
est: 434.04M (+13.0%)
|
462.45M
est: 661.23M (-30.1%)
|
808.99M
808.99M – 808.99M
+22.3% YoY
|
956.75M
956.75M – 956.75M
+18.3% YoY
|
| EBIT |
127.67M
est: 149.24M (-14.5%)
|
172.94M
est: 171.60M (+0.8%)
|
370.01M
est: 326.39M (+13.4%)
|
268.17M
est: 387.97M (-30.9%)
|
304.69M
est: 282.97M (+7.7%)
|
465.98M
est: 435.25M (+7.1%)
|
391.09M
est: 356.27M (+9.8%)
|
421.85M
est: 370.43M (+13.9%)
|
369.09M
est: 564.31M (-34.6%)
|
690.42M
690.42M – 690.42M
+22.3% YoY
|
816.52M
816.52M – 816.52M
+18.3% YoY
|
| Net Income |
100.27M
est: 82.13M (+22.1%)
|
145.19M
est: 100.44M (+44.5%)
|
306.80M
est: 253.76M (+20.9%)
|
221.75M
est: 277.55M (-20.1%)
|
250.49M
est: 175.78M (+42.5%)
|
402.57M
est: 294.20M (+36.8%)
|
328.38M
est: 261.64M (+25.5%)
|
345.26M
est: 339.63M (+1.7%)
|
209.77M
est: 209.77M (+0.0%)
|
300.68M
300.68M – 300.68M
+43.3% YoY
|
377.59M
377.59M – 377.59M
+25.6% YoY
|
| SGA |
53.15M
est: 49.02M (+8.4%)
|
61.18M
est: 56.36M (+8.6%)
|
111.53M
est: 107.20M (+4.0%)
|
111.09M
est: 127.42M (-12.8%)
|
91.52M
est: 92.93M (-1.5%)
|
132.20M
est: 142.95M (-7.5%)
|
120.52M
est: 117.01M (+3.0%)
|
111.16M
est: 116.39M (-4.5%)
|
174.62M
est: 177.31M (-1.5%)
|
216.94M
216.94M – 216.94M
+22.3% YoY
|
256.56M
256.56M – 256.56M
+18.3% YoY
|
| EPS |
0.15
est: 0.16 (-7.3%)
|
0.20
est: 0.20 (+1.1%)
|
0.43
est: 0.50 (-14.0%)
|
0.31
est: 0.55 (-43.3%)
|
0.36
est: 0.35 (+4.0%)
|
0.58
est: 0.58 (+0.1%)
|
0.47
est: 0.52 (-8.8%)
|
0.49
est: 0.49 (+0.9%)
|
0.30
est: 0.30 (+0.0%)
|
0.43
0.43 – 0.43
+43.3% YoY
|
0.54
0.54 – 0.54
+25.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 592.4K | 0.06% |
| 2 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 43.4K | 0.26% |
| 3 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 19.2K | 0.48% |
| 4 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 2.14M | 0.06% |
| 5 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 113.6K | 0.29% |
| 6 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 71.3K | 0.39% |
| 7 | Vanguard Total International Stock ETF VXUS | 0.00% | 2.20M | 0.05% |
| 8 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 27.0K | 0.28% |
| 9 | Vanguard Total World Stock ETF VT | 0.00% | 194.1K | 0.06% |
| 10 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 3.4K | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hailong Liu | GM & Director | — | male |
| Jie Yang | Deputy GM & Director | — | male |
| Rongming Bao | Board Secretary | — | male |
| Song Liu | Deputy GM & Director | — | male |
| Xi Liang Wang | Financial Director | — | male |
| Zhen Peng Gu | Deputy General Manager | — | male |
| Zhi Hai Sun | Accounting Supervisor | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 603360.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
